As The Commonwealth Fund celebrates 100 years, David Blumenthal, MD, MPP, looks back at the work it has done.
As The Commonwealth Fund celebrates 100 years, David Blumenthal, MD, MPP, looks back at the work it has done.
Transcript
This year, the Commonwealth Fund is celebrating their 100th year, and you have launched a website in commemoration. How has the organization worked to improve healthcare over the years?
Well, we have over the last 100 years we’ve been committed to improving the health of the American people as well as working on international issues and to improving the care, especially of vulnerable populations. Some of the things we’ve done over the years, we were among the original supporters of the Pap Smear. We’ve also helped fund rural hospitals in the south and that led to the program called the Hillburton Act which funded hospitals throughout the United States in the 40s and 50s. We were the first supporter of hospice in the United States, we funded a demonstration at Yale, and we were early on in supporting the development of health maintenance organizations. We were early funders of Harvard community health plan in Boston which was one of the first successful plans outside of the Kaiser pre-paid group pay practice model.
To visit the Commonwealth Fund's centennial website, click here.
Has the Commonwealth Fund done work internationally?
The Commonwealth Fund has also done a lot of international work and that’s becoming more interesting now to people in this particular time. We’re very proud of the fact that we have constantly demonstrated the alternatives and the availability of alternatives to the way we deliver care in the United States and we are continuing to do that. We believe that we have the best information available on alternative approaches to healthcare based on the other countries that we study intensively.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More